Observational studyScientific reports2025
Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Seric Molecular Markers Correlated with Stroke Rehabilitation Outcomes: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Mapping the Ischemic Continuum: Dynamic Multi-Omic Biomarker and AI for Personalized Stroke Care.International journal of molecular sciences · 2026Review
- Acupuncture in ischemic stroke: from local neuromodulation to metabolic reprogramming.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.